| Mr Peter Joseph Tucker, MD | |
|
815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109-4839 | |
| (717) 724-0720 | |
| (717) 724-0730 |
| Full Name | Mr Peter Joseph Tucker |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 31 Years |
| Location | 815 Sir Thomas Ct Ste 200, Harrisburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336149442 | NPI | - | NPPES |
| 50000019 | Other | PA | CAPITAL BLUE CROSS |
| 5258768 | Other | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD056753L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger St. Luke's Hospital | Orwigsburg, PA | Hospital |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Pinnacle Health Hospitals | Harrisburg, PA | Hospital |
| Schuylkill Medical Center - South Jackson Street | Pottsville, PA | Hospital |
| St Luke's Miners Memorial Hospital | Coaldale, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gslpg, Inc | 7810226875 | 227 |
News Archive
The American Chemical Society (ACS) invites news media to attend another in a continuing series of discussions with leading scientists, economists, and politicians on a wide range of timely scientific topics, including energy, nuclear terrorism, food safety, and climate and energy policy.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.
A medication use history is an integral part of the hospital admission process, but errors in the history may result in failure to detect drug-related problems or lead to interrupted or inappropriate drug therapy during hospitalization, according to background information in the article. Earlier studies suggest that these errors are a potentially serious safety issue.
PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.
› Verified 2 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
The American Chemical Society (ACS) invites news media to attend another in a continuing series of discussions with leading scientists, economists, and politicians on a wide range of timely scientific topics, including energy, nuclear terrorism, food safety, and climate and energy policy.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.
A medication use history is an integral part of the hospital admission process, but errors in the history may result in failure to detect drug-related problems or lead to interrupted or inappropriate drug therapy during hospitalization, according to background information in the article. Earlier studies suggest that these errors are a potentially serious safety issue.
PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.
› Verified 2 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
The American Chemical Society (ACS) invites news media to attend another in a continuing series of discussions with leading scientists, economists, and politicians on a wide range of timely scientific topics, including energy, nuclear terrorism, food safety, and climate and energy policy.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.
A medication use history is an integral part of the hospital admission process, but errors in the history may result in failure to detect drug-related problems or lead to interrupted or inappropriate drug therapy during hospitalization, according to background information in the article. Earlier studies suggest that these errors are a potentially serious safety issue.
PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.
› Verified 2 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
The American Chemical Society (ACS) invites news media to attend another in a continuing series of discussions with leading scientists, economists, and politicians on a wide range of timely scientific topics, including energy, nuclear terrorism, food safety, and climate and energy policy.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.
A medication use history is an integral part of the hospital admission process, but errors in the history may result in failure to detect drug-related problems or lead to interrupted or inappropriate drug therapy during hospitalization, according to background information in the article. Earlier studies suggest that these errors are a potentially serious safety issue.
PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Peter Joseph Tucker, MD 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109-4839 Ph: (717) 724-0720 | Mr Peter Joseph Tucker, MD 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109-4839 Ph: (717) 724-0720 |
News Archive
The American Chemical Society (ACS) invites news media to attend another in a continuing series of discussions with leading scientists, economists, and politicians on a wide range of timely scientific topics, including energy, nuclear terrorism, food safety, and climate and energy policy.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.
A medication use history is an integral part of the hospital admission process, but errors in the history may result in failure to detect drug-related problems or lead to interrupted or inappropriate drug therapy during hospitalization, according to background information in the article. Earlier studies suggest that these errors are a potentially serious safety issue.
PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.
› Verified 2 days ago
Mr. Emerson Leroy Knight Jr., MD Urology Medicare: Medicare Enrolled Practice Location: 304 N Paxtang Ave, Harrisburg, PA 17111 Phone: 717-982-8420 Fax: 717-564-6212 | |
Jose N Prudencio Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Mr. George Bernard Boline Jr., MD Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Mr. Frank Charles Damico, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Lewis E Harpster, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Vanessa Elliott, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 |